Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21
Via Investor Brand Network
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
From Brodsky & Smith LLC
Via GlobeNewswire
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25
Via Investor Brand Network
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
From Kahn Swick & Foti, LLC
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session. 
Via Benzinga
Topics Economy Stocks
6 Analysts Have This to Say About CymaBay Therapeutics
 
Via Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
 
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
Via Benzinga
Topics Stocks
Dow Up Triple Digits, Hits Fresh Highs
Stocks are on the rise today, as investors towards tomorrow's inflation data. 
Via Talk Markets
Topics Economy Stocks
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
Earnings Outlook For CymaBay Therapeutics
 
Via Benzinga
Where CymaBay Therapeutics Stands With Analysts
 
Via Benzinga
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences. 
Via InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
 
Via Benzinga
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue... 
Via Benzinga
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment. 
Via Investor's Business Daily
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
Via Investor's Business Daily
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
 
Via Benzinga
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
It became increasingly likely that seladelpar will ultimately gain regulatory approval. 
Via The Motley Fool
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.